report who inform consult preclin clinic aspect use immunomodul hiv infect geneva april world health organ global programm aid wide spectrum immunomodulatori strategi promis peopl hiv infect numer gap understand normal regul immun system progress hiv infect preclin develop immunomodul strong rational use substanc appropri laboratori studi vitro vivo preclin studi safeti therapeut agent assess potenti advers effect immun function viru replic therapeut modal preclin level clinic evalu strong rational safeti concern initi studi patient intermedi stage hiv diseas progress immunomodul unusu dose-respons pattern trial consult who forum time exchang valid inform develop clinic evalu immunomodul treatment individu hiv 